Hi Guys,
Resveratrol is the subject of much conjecture, with some studies making it sound like a panacea while others are not so sure. When we evaluate the so called French Paradox, we find a paradox in terms of information, originally it was stated that the French were amongst the highest consumers of fat in the world, other researchers have stated that while the French eat quite a bit of food, most of it is vegetable/fruit/salad. I think it will take a few more years before the red wine debate is finalised with agreement one way or the other, but in the meantime in the interest of maintaining a scientific base for debate here is a 2007 paper.


NCBI
PubMed A service of the U.S. National Library of Medicine
and the National Institutes of Health

* All Databases
* PubMed


1: Cancer Biol Ther. 2007 Dec;6(12):1833-6. Epub 2007 Oct 13.Click here to read Links
New enlightenment of French Paradox: resveratrol's potential for cancer chemoprevention and anti-cancer therapy.
Liu BL, Zhang X, Zhang W, Zhen HN.

Department of Neurosurgery, Xijing Institute of Clinical Neuroscience, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, PR China.

Resveratrol is a phytoalexin produced by many plants, and the skin of red grapes is particularly rich in resveratrol which accounts for the "French Paradox". Besides its protection of the cardiovascular system, it can affect the processes underlying all three stages of carcinogenesis, involving tumor initiation, promotion and progression. It has also been shown to suppress angiogenesis and metastasis. The anti-carcinogenic effects of resveratrol appear to be closely associated with its capacity to interact with multiple molecular targets involved in cancer development, while minimizing toxicity in normal tissues as tested. By reviewing many in vitro and in vivo studies, also considering both the supporting and challenging evidences, we are provided with a theory in support of the use of resveratrol in human cancer chemoprevention, in combination with either chemotherapeutic drugs or cytotoxic factors for the highly efficient treatment of drug refractory tumor cells. Anti-carcinogenic potential for cancer chemoprevention and anticancer therapy, which is one of the pleiotropic effects of resveratrol, is so called a new enlightenment of French Paradox.

PMID: 18087218 [PubMed - indexed for MEDLINE]

Cheers

Hi Guys,
This is the latest scientific trial on resveratrol published in April 2009, we have progressed a little bit further but still nothing in terms of human trials have been published, of a substantial nature, big trials from multiple sources are required to further this debate, along scientific lines of course.


NCBI
PubMed A service of the U.S. National Library of Medicine
and the National Institutes of Health

1: Cancer Prev Res (Phila Pa). 2009 May;2(5):409-18. Epub 2009 Apr 28.Click here to read Links
Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials.
Bishayee A.

Department of Pharmaceutical Sciences, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, 4209 State Route 44, Rootstown, OH 44272, USA. abishayee@neoucom.edu

Resveratrol (3,4',5-trihydroxy-trans-stilbene) is a dietary polyphenol derived from grapes, berries, peanuts, and other plant sources. During the last decade, resveratrol has been shown to possess a fascinating spectrum of pharmacologic properties. Multiple biochemical and molecular actions seem to contribute to resveratrol effects against precancerous or cancer cells. Resveratrol affects all three discrete stages of carcinogenesis (initiation, promotion, and progression) by modulating signal transduction pathways that control cell division and growth, apoptosis, inflammation, angiogenesis, and metastasis. The anticancer property of resveratrol has been supported by its ability to inhibit proliferation of a wide variety of human tumor cells in vitro. These in vitro data have led to numerous preclinical animal studies to evaluate the potential of this drug for cancer chemoprevention and chemotherapy. This review provides concise, comprehensive data from preclinical in vivo studies in various rodent models of human cancers, highlighting the related mechanisms of action. Bioavailability, pharmacokinetic, and potential toxicity studies of resveratrol in humans and ongoing interventional clinical trials are also presented. The conclusion describes directions for future resveratrol research to establish its activity and utility as a human cancer preventive and therapeutic drug.

PMID: 19401532 [PubMed - indexed for MEDLINE

Cheers

Hi Red Wine Worshipers,

From an old paper of not high standard, only 6 participants ie n=6 not enough to pay any attention really only a pilot study, but there did appear to be a potential problem in bioavailablity , leaving it unclear whether any resveratrol reached a target area.

From these research papers you can clearly see how manufacturer's jump the gun deliberately and start telling absolute lies to sell a product, and unbelievably people fall for it over and over again, and they in turn propagate these lies to a fertile field of believers.

Drug Metabolism and Disposition Fast Forward
First published on August 27, 2004; DOI: 10.1124/dmd.104.000885

HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS
Thomas Walle, Faye Hsieh, Mark H. DeLegge, John E. Oatis, Jr., and U. Kristina Walle

Department of Cell and Molecular Pharmacology and Experimental Therapeutics (T.W., J.E.O., U.K.W.) and Digestive Disease Center (M.H.D.), Medical University of South Carolina, Charleston, South Carolina; and Amgen, Inc., Thousand Oaks, California (F.H.)

The dietary polyphenol resveratrol has been shown to have chemopreventive activity against cardiovascular disease and a variety of cancers in model systems, but it is not clear whether the drug reaches the proposed sites of action in vivo after oral ingestion, especially in humans. In this study, we examined the absorption, bioavailability, and metabolism of 14C-resveratrol after oral and i.v. doses in six human volunteers. The absorption of a dietary relevant 25-mg oral dose was at least 70%, with peak plasma levels of resveratrol and metabolites of 491 ± 90 ng/ml (about 2 µM) and a plasma half-life of 9.2 ± 0.6 h. However, only trace amounts of unchanged resveratrol (<5 ng/ml) could be detected in plasma. Most of the oral dose was recovered in urine, and liquid chromatography/mass spectrometry analysis identified three metabolic pathways, i.e., sulfate and glucuronic acid conjugation of the phenolic groups and, interestingly, hydrogenation of the aliphatic double bond, the latter likely produced by the intestinal microflora. Extremely rapid sulfate conjugation by the intestine/liver appears to be the rate-limiting step in resveratrol's bioavailability. Although the systemic bioavailability of resveratrol is very low, accumulation of resveratrol in epithelial cells along the aerodigestive tract and potentially active resveratrol metabolites may still produce cancer-preventive and other effects.

Address correspondence to: Dr. Thomas Walle, Dept. of Pharmacology, Medical University of South Carolina, 173 Ashley Avenue, P.O. Box 250505, Charleston, SC 29425. E-mail: wallet@musc.edu

Cheers